Bharat Biotech, Biovet, Sapigen Biologix sign collaborative research pact with CSIR-IICT
To collaborate on the development of novel platform technologies for biotherapeutics and vaccines to support the indigenous, affordable healthcare solutions for humans and animals
Hyderabad: Bharath Biotech International, Biovet, and Sapigen Biologix have signed a joint master collaborative agreement (MCA) with CSIR-Indian Institute of Chemical Technology (CSIR-IICT) to collaborate on the development of novel platform technologies for biotherapeutics and vaccines to support the indigenous, affordable healthcare solutions for humans and animals.
The collaborators will identify the mutually interesting projects to pursue under the agreement. As a part of this MCA, the industry collaborators shall provide necessary financial support to CSIR-IICT for developing key raw material required by the collaborators, and also perform in-vitro and in vivo studies for further development of potential vaccine candidates and bio-therapeutics formulations to be designed by the collaborators.
The MCA follows the contribution by CSIR-IICT during February 2021, in developing a synthetic process route for adjuvant molecule TLR 7/8 to BBIL for Covaxin, an indigenous vaccine rolled out by Bharat Biotech. The partners intend to strengthen the working relationship between the two organisations, by conducting studies on futuristic vaccines, bio-therapeutic formulations, delivery strategies and also explore innovative solutions to the vaccination administration process.
The MCA was signed in presence of Dr Shekhar C Mande, DG CSIR and Dr Krishna M Ella, CMD, Bharat Biotech, by Dr Krishna Mohan, executive director, Bharat Biotech, Dr Jalachari Ella, director, Biovet and Dr Raches Ella, director, Sapigen Biologix and Dr S Chandrasekhar for CSIR-IICT.
Dr Shekhar C Mande said that the collaboration would help realise India’s Atma Nirbhar vision and contribute to disruptive technologies in the healthcare arena. The expertise of other CSIR labs will also be pooled in, if necessary, to take forward this vision.
Dr Krishna Ella said this is a big forward-thinking step, to explore future innovative solutions by design, and developing novel vaccine platforms in association with publicly-funded institutions such as the CSIR-IICT, by pushing the boundaries of the advanced technologies.
“We look forward to fortifying this collaboration and strengthening the innovation ecosystem of human and animal life sciences,” added Dr Krishna Ella.
Dr Srivari Chandrasekhar said that CSIR-IICT has mechanisms in place to deliver under dire uncertainties like the present pandemic situation, and this preparedness is exemplified in the development of synthetic processes of key adjuvants necessary for Covaxin in a short span of 2-3 months.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
